Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics (Nasdaq: ABEO) granted equity awards to new non-executive employees as material inducements to employment under Nasdaq Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Abeona Therapeutics (Nasdaq: ABEO) granted equity awards to new non-executive employees as material inducements to employment under Nasdaq Listing Rule 5635(c)(4). On July 31, 2026, Abeona’s Compensation Committee approved an aggregate of up to 10,800 restricted common shares, vesting in three equal annual installments over three years, subject to continued employment.
News Explained
The grants reserve up to 10,800 common shares for two new employees; because the awards vest over three years, they create potential dilution for existing holders as shares vest rather than issuing all shares immediately.
Details
News Market Reaction – ABEO
On Aug 3, the day this news came out, ABEO closed 0.47% below the previous close. Argus tracked a peak move of +3.6% during that session. Our momentum scanner recorded 34 alerts in the available session data.
Data tracked by StockTitan Argus for the Aug 3 session.
Key Figures
- Announcement date
- August 03, 2026
- News announcement
- Grant date
- July 31, 2026
- Restricted stock awards
- Recipients
- 2 individuals
- New Abeona hires
- Award size
- Up to 10,800 restricted shares
- Aggregate restricted stock awards
- Annual vesting tranche
- One-third of shares
- Vests yearly on each Grant Date anniversary
- Full vesting schedule
- Third anniversary of the Grant Date
- Subject to continued employment
Historical Context
-
Cincinnati Children's became Abeona's seventh qualified treatment center.
-
Five hires received restricted stock awards totaling up to 9,000 shares.
-
Restricted stock awards covered up to 13,800 shares for new employees.
-
Abeona announced participation in two June healthcare investor conferences.
-
Abeona reported $8.7 million in first-quarter net product revenue.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
restricted stock equity awards financial
vesting financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On July 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 10,800 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards is scheduled to vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee are scheduled to be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Contacts: Investor and Media Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor Lee M. Stern Meru Advisors lstern@meruadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.